<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156178</url>
  </required_header>
  <id_info>
    <org_study_id>ICG133-001</org_study_id>
    <nct_id>NCT04156178</nct_id>
  </id_info>
  <brief_title>CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies</brief_title>
  <official_title>Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate the Safety and Tolerability of CD20-CD19 cCAR in Patients With Relapsed and/or Refractory B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iCell Gene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Military General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>iCAR Bio Therapeutics Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iCell Gene Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, interventional, single arm, open label, treatment study to evaluate the
      safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical trials with CD19-directed CARs have achieved unprecedented remission rates as high
      as 90%. However, recent follow-up studies have shown a substantial portion of treated
      patients relapsed due to antigen escape. CD20-CD19 cCAR is a compound Chimeric Antigen
      Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressed on a
      T-cell, directed against the surface proteins CD20 and CD19. CD20-CD19 cCAR intends to target
      the mechanisms of single-CAR relapse, specifically antigen escape.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of dose-limiting toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse event by severity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of morphologic complete remission (CR), complete remission with incomplete recovery of counts (CR1), no residual disease as analyzed by flow cytometry analysis, and molecular remission by molecular studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>B Cell Lymphoma</condition>
  <condition>B Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>CD20-CD19 cCAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD20-CD19 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD20 and CD19 CARs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD20-CD19 cCAR T cells</intervention_name>
    <description>CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy</description>
    <arm_group_label>CD20-CD19 cCAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis based on the World Health Organization (WHO) 2008

          2. Histologically demonstrate CD19 or CD20 expressing B cell lymphoma or B ALL

          3. Patients have exhausted standard therapeutic options

          4. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped
             for more than 4 weeks

          5. Female must be not pregnant during the study

        Exclusion Criteria:

          1. Patients declining to consent for treatment

          2. Prior solid organ transplantation

          3. Potentially curative therapy including chemotherapy or hematopoietic cell transplant

          4. Prior treatment with CD20xCD3 or CD19x3 bispecific agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyu Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fang Liu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chengdu Military General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Pinz</last_name>
    <phone>6315386218</phone>
    <email>kevin.pinz@icellgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chengdu Military General Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fang Liu, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Shenzhen Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongyu Zhang, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD20</keyword>
  <keyword>CD19</keyword>
  <keyword>cCAR</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

